(Reuters) – Roche Holding AG (S:) on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp (O:) was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).
The drug, Gavreto, is an oral therapy which selectively targets so-called RET-altered cancers that have mutations that drive tumor growth, which are detected by a test approved by the U.S. Food and Drug Administration.
Swiss drugmaker Roche in July struck a pact worth up to $1.7 billion with Blueprint Medicines, for rights to Gavreto, which also awaits FDA approval for treating advanced RET mutant and RET fusion-positive thyroid cancers.
The drug will be jointly marketed in the United States and will be available within a week, Blueprint said.
Only about 1-2% of patients with NSCLC have RET fusions, according to Roche.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.